# Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone

> **NCT07381543** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 76 (estimated)

## Conditions studied

- Localized Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab Induction Therapy Group
- **DRUG:** Adebrelimab Maintenance Therapy Group

## Key facts

- **NCT ID:** NCT07381543
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381543, "Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07381543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*